









Markets
/
Stocks
/
nasdaq-iqv
/

IQVIA Holdings Inc

IQV

218.130USD

+0.300+0.14%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

37.08BMarket Cap

29.98P/E TTM



IQVIA Holdings Inc

218.130

+0.300+0.14%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of IQVIA Holdings Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IQVIA Holdings Inc's Score

Industry at a Glance

Industry Ranking

3 / 407

Overall Ranking

24 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 25 analysts

Buy

Current Rating

241.321

Target Price

+10.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

IQVIA Holdings Inc Highlights

StrengthsRisks

IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its segments include Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment offers mission-critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions segment serves biopharmaceutical customers and provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment offers health care providers (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Its Connected Intelligence delivers insights and solutions enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 15.40B.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 15.40B.

Overvalued

The company’s latest PE is 31.29, at a high 3-year percentile range.

Fairly Valued

The company’s latest PE is 29.70, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 175.08M shares, decreasing 0.69% quarter-over-quarter.

Held by David G. Herro

Star Investor David G. Herro holds 11.75M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.82, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 4.10B, representing a year-over-year increase of 5.24%, while its net profit experienced a year-over-year increase of 16.14%.

Score

Industry at a Glance

Previous score

8.82

Change



Financials

6.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.85

Key Metrics

Free cash flow

No Data

IQVIA Holdings Inc's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 8.11, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 29.70, which is 39.33% below the recent high of 41.38 and 37.72% above the recent low of 18.50.

Score

Industry at a Glance

Previous score

8.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.16, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for IQVIA Holdings Inc is 250.00, with a high of 268.43 and a low of 200.00.

Score

Industry at a Glance

Previous score

8.16

Change

Support & Resistance

No Data

Analyst Rating

Based on 25 analysts

Buy

Current Rating

241.321

Target Price

+10.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

IQVIA Holdings Inc

IQV

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

BeOne Medicines AG

ONC

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 8.81, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 229.35 and the support level at 201.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.99

Change

-0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

1.221

Buy

RSI(14)

66.661

Neutral

STOCH(KDJ)(9,3,3)

70.704

Neutral

ATR(14)

6.539

Low Volatility

CCI(14)

66.986

Neutral

Williams %R

26.312

Buy

TRIX(12,20)

0.573

Sell

StochRSI(14)

0.874

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

218.764

Sell

MA10

215.270

Buy

MA20

209.149

Buy

MA50

195.960

Buy

MA100

183.816

Buy

MA200

177.959

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 102.99%, representing a quarter-over-quarter increase of 5.03%. The largest institutional shareholder is The Vanguard, holding a total of 19.60M shares, representing 11.51% of shares outstanding, with 1.06% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

19.60M

-0.82%

Harris Associates L.P.

Star Investors

11.75M

+5.23%

BlackRock Institutional Trust Company, N.A.

9.37M

-5.13%

State Street Investment Management (US)

7.62M

-1.27%

GIC Private Limited

6.54M

-28.36%

Geode Capital Management, L.L.C.

4.22M

-0.40%

CPP Investment Board

4.17M

-9.28%

Farallon Capital Management, L.L.C.

3.85M

+12.88%

AllianceBernstein L.P.

3.56M

+0.55%

Artisan Partners Limited Partnership

3.27M

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 7.20, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.